Bergen, Norway, February 21st, 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces today that the Board of Directors has decided to prepare for submitting application for listing of Lifecare’s shares at the main list of Oslo Stock Exchange (OSE), transferring from the current listing on Euronext Growth.
– Stepping up to the major league at OSE is an important decision for Lifecare. We are comfortable with our organization’s capability to adhere to the strict requirements and obligations connected with being listed at OSE, says CEO Joacim Holter at Lifecare.
Lifecare has been through a year with several milestone achievements when it comes to proof of concept of our cutting edge Sencell sensor. The company’s CGM technology has proven its competitive properties in terms of accuracy, robustness, and longevity.
– We are now really on the brink of automated pilot production, and we see a new era for our sensor technology. We expect that a listing on the main list at Oslo Stock Exchange will further accelerate the overall growth of our company, attract, and secure a more flexible and even broader investor base that will support Lifecare in reaching our growth targets. We also expect that an uplisting will increase share liquidity and strengthen the profile of Lifecare, says Holter.
In accordance with the Board of Directors’ decision, Lifecare management will prepare to submit the application for listing on OSE in the course of Q3 2024. The Board of Director’s outlook for the Lifecare share is to be ready for trading on Oslo Børs’ main list in October 2024, says Joacim Holter.